ANDA > Nova Content
Written by Marc Chatenay-Lapointe, Ph.D. and Jing Liu, Ph.D.
On March 13, 2017, the use of Novartis cell cycle inhibitor Kisqali® (ribociclib, LEE011) in... Read More »
Written by Daniel K. Yarbrough, Ph.D. and Kerry S. Taylor, Ph.D.
Bevacizumab (Avastin®) is the subject of the widely watched “patent dance”... Read More »
Market intelligence is especially critical to sound pharmaceutical investing
Pharmaceutical investing is both challenging and potentially very rewarding, but it... Read More »
Written by Mark E. Davis and Kerry S. Taylor, Ph.D.
The PTAB issued two final written decisions upholding The University of Pennsylvania’s claims to methods ... Read More »
Written by Sabrina Wang and Adam Powell
The Federal Circuit held that a rat study in a provisional application and a conversion method in an uncited reference did ... Read More »
Written by Kerry S. Taylor, Ph.D. and Nathanael Luman, Ph.D.
The PTAB issued a Final Written Decision upholding Pozen’s ulcer reducing Vimovo® claims... Read More »
Written by Caleb A. Bates, Ph.D. and Agnes Juang, Ph.D.
On January 12, 2017, the U.S. Court of Appeals for the Federal Circuit issued an opinion affirming the... Read More »
Written by Daniel K. Yarbrough, Ph.D. and Nathanael R. Luman, Ph.D.
The PTAB denied institution of an IPR based on patent owner’s challenge to the prior art ... Read More »
By Barry Herman
By now, most everyone in the patent community has heard about the $2.54 Billion dollar jury verdict in a battle over Hepatitis C medication that... Read More »
Written by Robert J. Hilton, Ph.D. and Jing Liu, Ph.D.
On January 13, 2017, the Supreme Court granted certiorari in Amgen v. Sandoz, 794. f. 3d 1347 (Fed. Cir... Read More »
Written by Jane Xia and Jason J. Jardine
Every year, the FDA’s Center for Drug Evaluation and Research (CDER) approves new medications. Some medications are ... Read More »
Written by Marc Chatenay-Lapointe, Ph.D. and Michael L. Fuller
On December 23, 2016, the U.S. Food and Drug Administration approved SPINRAZA™ (nusinersen)... Read More »
Written by Eric S. Furman, Ph.D. and Caleb A. Bates, Ph.D.
On November 21, 2016, the U.S. Court of Appeals for the First Circuit upheld a 2014 jury verdict for... Read More »
The size of businesses sued most frequently for patent infringement in 2016 were significantly larger than in 2015, when five little-known patent holders were among... Read More »
Currently there are two competing patent reform bills making the rounds in Congress: Representative Goodlatte’s Innovation Act of 2015 and the Strong Patent Act ... Read More »
Penicillin, teflon, plastic, and now nanoparticles; all breakthrough discoveries stemming from scientific “failures.” University of Central Florida... Read More »
In... and out. In... and out. Air flows through the narrow channel carved into the small silicon chip, blood pumping, the miniature lung embedded inside breaths... Read More »
Mobile health apps are developing quickly, and they aim to replace and/or complement treatments prescribed by doctors. The newest app on the block is Happitique. This ... Read More »
Here’s the top medical news of this week!
Promising new HIV treatments give hope for eventual cure
The Human Immunodeficiency Virus (HIV)... Read More »
This week, Roche announced it has discontinued development of its cholesterol drug dalcetrapib, marking the end of the story for a drug once touted as a potential... Read More »